Bazedoxifene/conjugated estrogens

The drug combination bazedoxifene/conjugated estrogens (trade name Duavee in the US) is a medication approved by the Food and Drug Administration (FDA) for the treatment of menopause symptoms and postmenopausal osteoporosis.[1] It is a fixed-dose combination drug containing the selective estrogen receptor modulator bazedoxifene and conjugated estrogens being marketed by the pharmaceutical company Pfizer.

Bazedoxifene/conjugated estrogens
Combination of
BazedoxifeneSelective estrogen receptor modulator
Conjugated estrogensEstrogen
Clinical data
Trade namesDuavee
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
ChemSpider
  • None
KEGG

Duavee was approved by the US FDA on October 3, 2013, for use as a once-daily tablet.

See also

References
  1. "Duavee. Generic Name: conjugated estrogens and bazedoxifene tablets". rxlist.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.